Journal of Clinical Pharmacy and Therapeutics · 2005 · 21 citations · 13 references
MedicineHematologyOncologyHematologic OncologyMedical OncologyOncology PharmacotherapyHematologic MalignanciesHematologic Malignancy TherapyHematologic ToxicityMalignant NeoplasmsRadiation TherapyTumor Lysis SyndromeAbdominal DiscomfortAllogeneic Stem Cell TherapyChronic Myeloid Leukemia TherapyHydroxyurea TherapyMyeloid NeoplasmsSplenic Leukemic InfiltrationTyrosine Kinase Inhibitor Therapy
Therapeutic agents for chronic myeloid leukaemia (CML) in the chronic phase include hydroxyurea, interferon alpha, allogeneic stem cell transplantation and the tyrosine kinase inhibitor imatinib (STI 571, Gleevec). For elderly patients, oral hydroxyurea is suitable for the relief of symptoms caused by hyperleukocytosis, and splenic irradiation would be considered if abdominal discomfort or fullness induced by splenomegaly were present. Tumour lysis syndrome (TLS) is seldom seen in the treatment for CML, and TLS caused by hydroxyurea or splenic irradiation is rarely observed. Herein, we report an elderly CML patient who received treatment with hydroxyurea, allopurinol, hydration and splenic irradiation. After 3 days, acute TLS developed. Aggressive supportive treatment, including haemodialysis, stabilized the condition.
13
An overview of the clinical experience with hydroxyurea.
Ross C. Donehower · PubMed · 1992 · 158 citations
George W. Santos · Current Opinion in Oncology · 1990 · 64 citations
Medicine, Hematology, Pediatrics +11
Uremia Following X-Ray Therapy in Leukemia
Dudley Merrill · New England Journal of Medicine · 1940 · 37 citations
Medicine, Hematology, Oncology +11